Dr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.

Dr. Reddys shares rose over 4% after announcing a global biosimilar partnership with Alvotech for Keytruda. Q4FY25 profit ...

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, ...

Dr Reddy's Laboratories and Alvotech join forces to co-develop and commercialize a biosimilar to Keytruda (pembrolizumab) for ...

CHENNAI: Shares of Dr Reddy’s Laboratories surged over 3% in early trade on Thursday after the Indian drug maker announced a ...

Alvotech and Dr Reddy's entered into a collaboration and license agreement to co-develop, manufacture and commercialize a ...

LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and ...

Under the agreement signed between the two companies, Alvotech and Dr. Reddy’s will be jointly responsible for developing and ...

The total equity share capital, or total voting capital, of Dr. Reddy's Laboratories Ltd. considered for these calculations ...

Dr Reddy's announced a strategic partnership with Alvotech to develop a biosimilar to Keytruda, a top-selling cancer therapy ...